1. Home
  2. RXO vs ADMA Comparison

RXO vs ADMA Comparison

Compare RXO & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RXO Inc.

RXO

RXO Inc.

HOLD

Current Price

$18.17

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$10.32

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXO
ADMA
Founded
2022
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.4B
IPO Year
2022
2012

Fundamental Metrics

Financial Performance
Metric
RXO
ADMA
Price
$18.17
$10.32
Analyst Decision
Hold
Strong Buy
Analyst Count
13
4
Target Price
$16.33
$25.67
AVG Volume (30 Days)
1.7M
4.7M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
72.81
N/A
EPS
N/A
0.60
Revenue
$5,742,000,000.00
$42,219,783.00
Revenue This Year
$0.49
$27.46
Revenue Next Year
$6.90
$22.11
P/E Ratio
N/A
$17.16
Revenue Growth
26.20
43.85
52 Week Low
$10.43
$7.21
52 Week High
$20.38
$23.98

Technical Indicators

Market Signals
Indicator
RXO
ADMA
Relative Strength Index (RSI) 53.94 39.94
Support Level $16.17 $7.21
Resistance Level $18.69 $11.42
Average True Range (ATR) 0.96 0.48
MACD -0.18 0.10
Stochastic Oscillator 42.27 15.69

Price Performance

Historical Comparison
RXO
ADMA

About RXO RXO Inc.

RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: